Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost–effectiveness and budget impact

To evaluate the cost–effectiveness of intravenous ferric carboxymaltose (FCM) versus placebo for the management of iron deficiency in patients with chronic heart failure in the Italian healthcare system and to estimate its impact on the national healthcare budget. A Markov model was developed to pro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2019-10, Vol.8 (11), p.1099-1110
Main Authors: Rognoni, Carla, Gerzeli, Simone
Format: Article
Language:English
Subjects:
budget impact analysis
chronic heart failure
Cost analysis
cost–effectiveness analysis
cost–utility analysis
Edema
Expenditures
ferric carboxymaltose
Heart failure
Hospitals
Hypotheses
Impact analysis
Laboratories
Literature reviews
Patients
Quality of life
Questionnaires
Software
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the cost–effectiveness of intravenous ferric carboxymaltose (FCM) versus placebo for the management of iron deficiency in patients with chronic heart failure in the Italian healthcare system and to estimate its impact on the national healthcare budget. A Markov model was developed to project costs and health outcomes over 1 year, based on data from literature. Healthcare resources consumption was derived from an e-survey administered to clinicians. Costs were obtained from official tariffs. Treatment with FCM represents a dominant strategy compared with placebo, leading to national budget annual savings of 20–97 million Euros, according to different increasing utilization rates. FCM is a cost-saving option for the treatment of chronic heart failure patients with iron deficiency in Italy.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer-2019-0074